Sana Biotechnology

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sana Biotechnology Inc (NASDAQ: SANA) has obtained non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct from IASO Biotherapeutics and Innovent Biologics. The constructs can be used in certain in vivo gene therapy and ex vivo hypoimmune cell therapy applications.

Sana Biotechnology Inks Two Licensing Pacts For Targets Against Hematological Malignancies

License will enable Sana's in vivo and ex vivo engineered T cell programs for B cell malignancies

Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct

Agreement combines IASO Bio and Innovent's CAR construct, validated in clinical trials, with Sana's in vivo and ex vivo engineered cell therapy programs Agreement combines IASO Bio and Innovent's CAR construct, validated in clinical trials, with Sana's in vivo and ex vivo engineered cell therapy programs

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 40th Annual J.P. Morgan Healthcare Conference at 10:30 a.m. PT on Tuesday, January 11, 2022. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference

Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells

Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs

SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during four poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held both in person in Atlanta, GA and virtually from Sunday, December 11 to Tuesday, December 14, 2021.

Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting

Beam Therapeutics

Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs. The license does not include any rights to base editing using Cas12b, which remains at Beam.

Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology

Sana Biotechnology has a new $50 million tool in its toolbox.

Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics

Agreement combines Beam's gene editing technology with Sana's ex vivo platform

Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Morgan Stanley 19th Annual Global Healthcare Conference at 2:00 p.m. PT on Monday, September 13, 2021. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Ranpak Holdings Corp

UnitedHealth Group

Two new Breakout Stocks for Week 34 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges® the portfolio is up +49.8% YTD with a record 19 out of 33 weeks this year in negative signal conditions above the 40 MG level.

Week 34 MDA Breakout Stocks - August 2021: Short-Term Picks To Give You An Edge

Sana Biotechnology Inc (NASDAQ: SANA) has entered into a lease agreement to develop a 163,000 square foot manufacturing facility in Fremont, California.  The facility will support the manufacture of Sana's late-stage clinical development and early commercial product candidates.

Sana Biotech To Establish Manufacturing Facility For Gene, Cell Therapy Candidates

Facility to Support Allogeneic CAR T, Gene Therapy, and Stem Cell-Derived Therapies

Sana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Product Candidates

Sana is the category leader for hypoimmune cell therapies that has the potential to transform diseases from oncology to CNS disorders and liver disease. Early data is promising, showing Sana's ability to design cells that can evade the host immune system and unlocking new therapeutic applications.

Sana Biotechnology: Hypoimmune Cell Therapies

First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression

Sana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates

SEATTLE , June 14, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during two plenary sessions at the International Society for Stem Cell Research 2021 Virtual Annual Meeting, to be held Monday, June 21 through Saturday, June 26.

Sana Biotechnology to Present During Plenary Sessions at ISSCR 2021 Virtual Annual Meeting

SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference at 12:00 p.m. PT on Wednesday, June 9, 2021. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

Presented key proof of concept data for multiple platforms at AACR 2021

Sana Biotechnology Reports First Quarter 2021 Financial Results and Business Updates

— Fusogen platform demonstrates potential for cell-specific in vivo delivery of gene therapies to multiple cell types, including T cells and hepatocytes —

Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021

– Targeted in vivo gene delivery of a CAR using a CD8-specific fusogen results in tumor eradication – – Hypoimmune CAR T cells protected from innate and adaptive immune cell recognition and result in tumor eradication –

Sana Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2021

Expects to present data at multiple scientific conferences in 2021

Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates

Biogen

Fate Therapeutics

Gilead Sciences

Johnson & Johnson

Orchard Therapeutics plc - ADR

Sangamo Therapeutics

Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.

Regenerative Medicine Attracted Record $20 Billion in Funding in 2020

MADISON, Wis. and SEATTLE, March 17, 2021 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, announced today that Sana has been granted a non-exclusive right to use FUJIFILM Cellular Dynamics' iPSC platform for the development of commercial cell therapies. As a treatment modality, cell therapies have the potential to augment, repair, or replace human biology, including organs, tissues and cells.

FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell Therapies

Axcella Health Inc

Codiak Biosciences

Denali Therapeutics

Evelo Biosciences Inc

Foghorn Therapeutics

Kaleido Biosciences Inc

Seres Therapeutics

Moderna

Rubius Therapeutics Inc

Sigilon Therapeutics

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing. The round included contributions from funds...

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target

A bet on Sana is essentially a bet on management given that all the company's drugs are in the preclinical stage. As the example of Juno shows, though the company may be a winning proposition in the near term, success in terms of drug development is far from guaranteed.

Sana Biotechnology: An Ultra-Risky Bet

News for Sana Biotechnology Stock (SANA)